Krisztina Zsebo, Ph.D., VasoRx CEO, Director, and Co-founder Dr. Zsebo is a biopharmaceutical veteran with 35 years of experience in the Biotechnology industry and has been involved in numerous successful ventures. She was CEO & President of Celladon Corporation, for 11 years and took the company public. She was also an Entrepreneur in Residence at Enterprise Partners Venture Capital. Prior to joining Enterprise, she was CEO & President of Remedyne Corporation. Before coming to Remedyne she was Executive Vice President of Connetics Corporation. Dr. Zsebo also headed the Biopharmaceutical and Implant Division of ALZA Corporation, where she was responsible for the division which developed and filed the NDA for Viadur®, an implantable drug/device for prostate cancer patients. At Cell Genesys, where she was Executive Vice President of Research and Product Development, she managed the Xenotech division where Xenomouse was developed. It was spun off to become Abgenix, one of the most successful biotech companies. Earlier in her career, Kris spent eight years at Amgen in research and product development where she worked on the discovery of NEUPOGEN®, as well as Stem Cell Factor, and various aspects of EPOGEN® development. Dr. Zsebo received a B.S. in Biochemistry from the University of Maryland, a M.S. in Biochemistry and Biophysics from Oregon State University and a PhD in Comparative Biochemistry and Molecular Biology from the University of California, Berkeley.
Jeff Rudy, VasoRx Chief Operating Officer Jeff Rudy has 28 years of clinical research and development experience across multiple therapeutic areas at a number of large and small pharmaceutical companies. For the past 14 years, he has worked on advanced therapies (cell and gene therapy) for cardiovascular indications at a number of startup biotech companies (XyloCor Therapeutics, Capricor and Celladon), serving on the senior executive teams as Vice President of Clinical Operations and Research & Development Operations. Prior to Celladon, he was Senior Director at Pfizer and held positions at Gilead Sciences, Cell Genesys and Amgen. Mr. Rudy received a B.S. in Microbiology from The Ohio State University